The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Starglo isn't applicable to a US population, an adcom rules.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
PF-08046037 joins PF-08046054 in clinical development.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.